OraSure Targets HIV-1/2, Hepatitis Tests To Grow Business To $250 Mil.
This article was originally published in The Gray Sheet
Executive Summary
OraSure is setting its sights on obtaining FDA approval of an OraQuick HIV-2 rapid oral fluid test, as well as licensing rights from Bio-Rad for the antibody patents, following approval of an HIV-1 version March 26
You may also be interested in...
OraSure Taps Former J&J Exec For CEO Post; OraQuick Obtains CLIA Waiver
Newly appointed OraSure President & CEO Douglas Michels will rely on international marketing experience gained at Ortho-Clinical Diagnostics to build a rapid infectious disease test presence outside the U.S
OraSure Taps Former J&J Exec For CEO Post; OraQuick Obtains CLIA Waiver
Newly appointed OraSure President & CEO Douglas Michels will rely on international marketing experience gained at Ortho-Clinical Diagnostics to build a rapid infectious disease test presence outside the U.S
OraSure HIV test nears market entry
Firm targets "mid-summer" launch for its combined OraQuick HIV-1/2 rapid oral fluid test. Prior to launch, OraSure must obtain licensing rights for the test's HIV-2 marker from Bio-Rad and a Clinical Laboratory Improvement Amendments (CLIA) waiver for the diagnostic's oral fluid component. Further, the firm needs FDA clearance for the test's HIV-2 portion; the HIV-1 part received clearance March 26. OraSure plans to submit HIV-2 data and completed clinical tests for the CLIA waiver by June (1"The Gray Sheet" March 29, 2004, p. 3)...